Preliminary subscription rate of Rights Issue in Simris Group AB (Publ) amounts to approximately 57 percent
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.
The preliminary outcome of the Rights Issue in Simris Group AB (publ) (“Simris Group” or the “Company”), the subscription period of which ended at 3:00 p.m. today, August 16, 2023, indicates that 51,341,938 new shares were subscribed for with and without support of subscription rights, corresponding to approximately 57 percent of the Rights Issue. The Rights Issue was fully secured through subscription commitments and underwriting agreements, and Simris Group will therefore receive the maximum amount of SEK 24,3m before issuance costs. Together with commitments associated with the Directed Issue previously announced by Simris, the Company will receive approximately SEK 40,5m before issuance costs.
The preliminary outcome indicates that approximately 55 percent of the Rights Issue was subscribed for with subscription rights, and approximately 2 percent without subscription rights. The Company will therefore utilise subscription commitments and underwriting agreements amounting to 43 percent of the Rights Issue.
The final outcome of the Rights Issue is expected to be announced on August 18, 2023. Shares will be allocated according to the principles set out in the information memorandum published on July 31, 2023. Information on allocation of shares subscribed for without support of subscription rights will be sent out to those who are allocated shares on August 18th, 2023, in the form of settlement notes.
The subscribed and allocated shares must be paid in cash according to the instructions on the settlement note. Shareholders registered with a nominee will be notified of their allocation in accordance with the nominee’s procedures. Only those who have been allotted shares will be notified.
Simris Group will receive the maximum of SEK 24,3m from the Rights Issue and before issuance costs. Together with commitments associated with the Directed Issue previously announced by Simris, the Company will receive approximately SEK 40,5m before issuance costs.
Simris CEO, Julian Read commented, “considering the market conditions and summer vacation timing, the result of the Rights Issue is in-line with our cautious expectations. It was important that the Rights Issue was 100% secured so that investors could subscribe with a high level of confidence, knowing that the SEK 24,3m Rights Issue was guaranteed. We are grateful to existing shareholders that have demonstrated their continued support for Simris and we are delighted to have attracted significant new investors, with a commitment to the long-term and a specific interest in the field of Antibody Drug Conjugates. Now that the transaction has closed the Board and Management of the Simris Group will review the outcome considering the opportunities before us”.